LifeMD (NASDAQ:LFMD) Price Target Lowered to $8.00 at B. Riley Financial

LifeMD (NASDAQ:LFMD) had its price objective cut by research analysts at B. Riley Financial from $10.00 to $8.00 in a report released on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. B. Riley Financial’s price target points to a potential upside of 142.72% from the company’s previous close.

Several other equities research analysts have also weighed in on LFMD. BTIG Research reduced their target price on LifeMD from $10.00 to $9.00 and set a “buy” rating for the company in a report on Thursday. Weiss Ratings reaffirmed a “sell (d)” rating on shares of LifeMD in a research report on Tuesday. UBS Group reissued a “buy” rating on shares of LifeMD in a report on Wednesday, May 27th. Zacks Research lowered shares of LifeMD from a “hold” rating to a “strong sell” rating in a report on Friday, July 17th. Finally, Wall Street Zen cut shares of LifeMD from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. Eight investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $8.57.

LifeMD Stock Down 10.4%

Shares of LifeMD stock traded down $0.38 on Thursday, hitting $3.30. 1,854,133 shares of the company traded hands, compared to its average volume of 1,070,411. LifeMD has a 12-month low of $2.56 and a 12-month high of $7.32. The company has a market cap of $159.40 million, a PE ratio of 65.93 and a beta of 2.02. The company has a 50-day moving average price of $4.43 and a 200 day moving average price of $3.98.

LifeMD (NASDAQ:LFMD) last issued its earnings results on Wednesday, August 5th. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.01). The firm had revenue of $47.28 million during the quarter, compared to analysts’ expectations of $49.16 million. LifeMD had a net margin of 2.37% and a negative return on equity of 150.88%. Equities research analysts anticipate that LifeMD will post -0.37 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Vanguard Group Inc. grew its position in LifeMD by 6.7% during the third quarter. Vanguard Group Inc. now owns 2,226,871 shares of the company’s stock valued at $15,120,000 after buying an additional 140,749 shares during the period. Federated Hermes Inc. increased its stake in shares of LifeMD by 278.1% during the 4th quarter. Federated Hermes Inc. now owns 980,285 shares of the company’s stock worth $3,343,000 after purchasing an additional 721,018 shares during the last quarter. Geode Capital Management LLC lifted its stake in LifeMD by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 959,700 shares of the company’s stock valued at $3,273,000 after purchasing an additional 11,324 shares during the last quarter. Royce & Associates LP grew its holdings in LifeMD by 11.7% during the fourth quarter. Royce & Associates LP now owns 909,651 shares of the company’s stock valued at $3,102,000 after purchasing an additional 95,200 shares during the period. Finally, Whetstone Capital Advisors LLC lifted its position in shares of LifeMD by 89.6% during the 4th quarter. Whetstone Capital Advisors LLC now owns 703,053 shares of the company’s stock valued at $2,397,000 after buying an additional 332,269 shares during the last quarter. 35.52% of the stock is owned by institutional investors.

Key Stories Impacting LifeMD

Here are the key news stories impacting LifeMD this week:

• Positive Sentiment: LifeMD reported second-quarter revenue of $47.3 million, within its guidance range, while active subscribers grew 20% year over year to approximately 356,000. Weight Management subscribers reached about 108,000. LifeMD Reports Second Quarter 2026 Results
• Positive Sentiment: Gross margin expanded to approximately 89% from 86% a year earlier, helped by lower shipping and fulfillment costs and the scaling of LifeMD’s in-house pharmacy. The adjusted EBITDA loss improved 21% sequentially to roughly $3.5 million.
• Positive Sentiment: LifeMD said approximately 95% of new weight-management patients now start branded GLP-1 therapies, and expects to return to positive adjusted EBITDA in the second half of 2026. The company ended the quarter with $25.1 million in cash, no debt and $30 million available under its revolving credit facility.
• Neutral Sentiment: The transition away from compounded GLP-1 medications is reducing upfront revenue but is intended to create longer-duration memberships and more predictable recurring revenue. Management also highlighted an XYOSTED® telehealth collaboration and expanding Women’s Health, pharmacy, insurance and enterprise opportunities. LifeMD Reports Second Quarter 2026 Results, Reaches Branded GLP-1 Transition Milestone and Raises Full-Year Guidance
• Negative Sentiment: GAAP loss attributable to common stockholders widened to $7.9 million, or $0.16 per share, from $3.8 million, or $0.09 per share, in the prior-year quarter. Revenue also fell from $49.0 million, and was below the approximately $49.2 million analyst consensus cited in the reports.
• Negative Sentiment: Management cut full-year 2026 revenue guidance to $205.5 million-$212.5 million from $220 million-$230 million. Adjusted EBITDA guidance was reduced to a loss of $6 million through breakeven from $12 million-$17 million, while third-quarter revenue guidance of $48 million-$51 million is below consensus expectations. LifeMD Reports Q2 Loss, Lags Revenue Estimates

About LifeMD

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.